目的 分析瑞舒伐他汀對不穩(wěn)定型心絞痛患者冠狀動脈支架植入術(shù)后的心肌保護(hù)作用。方法 選擇2014年1月~2016年5月陜西省核215醫(yī)院收治的擇期行冠狀動脈支架植入術(shù)的不穩(wěn)定型心絞痛患者90例為研究對象，根據(jù)入院治療病例號順序分為觀察組和對照組，每組45例，對照組在常規(guī)治療的基礎(chǔ)之上加用阿托伐他汀，觀察組在常規(guī)治療的基礎(chǔ)上加用瑞舒伐他汀，比較兩組肌酸激酶同工酶（CK-MB）、心肌肌鈣蛋白（cTnI）、人心型脂肪酸結(jié)合蛋白（h-FABP）以及超敏C反應(yīng)蛋白（hs-CRP）、腫瘤壞死因子-α（TNF-α）、干擾素-γ（INF-γ）、白介素-6（IL-6）白介素-10（IL-10）、白介素-18（IL-18）水平。記錄兩組治療過程中的藥物不良反應(yīng)及心臟不良事件發(fā)生情況。結(jié)果 術(shù)后24 h，兩組的CK-MB、cTnI水平均較術(shù)前顯著升高（P<0.05），但觀察組的CK-MB、cTnI水平低于對照組（P<0.05），兩組h-FABP水平術(shù)前術(shù)后及組間比較，差異均無統(tǒng)計(jì)學(xué)意義；術(shù)后觀察組和對照組的hs-CRP、TNF-α、INF-γ、IL-10、IL-18水平均較術(shù)前升高（P<0.05），且對照組的水平均顯著高于觀察組（P<0.05）；術(shù)后，觀察組的IL-6高于術(shù)前，但差異無統(tǒng)計(jì)學(xué)意義，對照組的IL-6水平顯著高于術(shù)前和術(shù)后觀察組（P<0.05）。兩組藥物不良反應(yīng)及心臟不良事件發(fā)生情況比較，差異無統(tǒng)計(jì)學(xué)意義。結(jié)論 與同劑量阿托伐他汀相比，瑞舒伐他汀改善心肌損傷和炎癥狀態(tài)的效果更優(yōu)，且不增加不良反應(yīng)。

Objective To investigate the myocardial protective effects of rosuvastatin in patients with unstable angina pectoris undergoing coronary stent implantation.Methods Patients (90 cases) with unstable angina pectoris undergoing coronary stent implantation in No. 215 Hospital of Shanxi Nuclear Industry from January 2014 to May 2016 were divided into observation group and control group, 45 cases in each group. Patients in the observation group were treated with rosuvastatin, and patients in the control group were treated with atorvastatin. The levels of CK-MB, cTnI, h-FABP, hs-CRP, TNF-α, INF-γ, IL-6, IL-10, and IL-18 were compared between two groups. Adverse drug reaction and major adverse cardiac events of two groups were recorded.Results After 24 h operation, the levels of CK-MB, cTnI, hs-CRP, TNF-α, INF-γ, IL-10, and IL-18 of two group were significantly higher than those before operation (P<0.05), and those in observation group were significantly lower than control group (P<0.05). There was no difference in h-FABP between two groups before and after operation (P<0.05). The level of IL-6 in the observation group after operation was higher than that before operation, but the difference was not significant (P<0.05); The level of IL-6 in the control group was significantly higher than that before operation and that of observation group (P<0.05); The rates of drug adverse reactions and major adverse cardiac events were similar in two groups.Conclusion Compared with same doseatorvastatin, the effects of rosuvastatin in muscle damage and inflammatory response are better, and do not increase adverse reactions.